0001104659-23-102132.txt : 20230920 0001104659-23-102132.hdr.sgml : 20230920 20230920080015 ACCESSION NUMBER: 0001104659-23-102132 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230914 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20230920 DATE AS OF CHANGE: 20230920 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Armata Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0000921114 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911549568 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37544 FILM NUMBER: 231265317 BUSINESS ADDRESS: STREET 1: 4503 GLENCOE AVENUE CITY: MARINA DEL REY STATE: CA ZIP: 90292 BUSINESS PHONE: 310-665-2928 MAIL ADDRESS: STREET 1: 4503 GLENCOE AVENUE CITY: MARINA DEL REY STATE: CA ZIP: 90292 FORMER COMPANY: FORMER CONFORMED NAME: AmpliPhi Biosciences Corp DATE OF NAME CHANGE: 20130222 FORMER COMPANY: FORMER CONFORMED NAME: TARGETED GENETICS CORP /WA/ DATE OF NAME CHANGE: 19940331 8-K 1 tm2326466d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 14, 2023

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Washington		001-37544		91-1549568
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(IRS Employer Identification No.)

5005 McConnell Avenue Los Angeles, California		90066
(Address of principal executive offices)		(Zip Code)

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		ARMP		NYSE American

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On September 15, 2023, Richard Rychlik, Corporate Controller of Armata Pharmaceuticals, Inc. (“Armata” or the “Company”), was promoted to serve as Armata’s principal financial officer, replacing Julianne Averill of Danforth Advisors, LLC, who resigned as Chief Financial Officer on the same day. The promotion of Mr. Rychlik is part of Armata’s plan to transition more of its financing and accounting functions to Armata personnel. Armata anticipates that Danforth Advisors, LLC will continue to support Armata during that transition.

Mr. Rychlik, age 67, has served as the Company’s Corporate Controller since September 5, 2023. Prior to joining Armata, Mr. Rychlik served as corporate controller at ArmaGen Inc., a clinical stage biopharma research company, acquired by JCR Pharma, from 2017 until September 2023. As corporate controller at ArmaGen Inc., Mr. Rychlik managed financial reporting, prepared budgets and forecasts, and prepared and coordinated due diligence for M&A transactions. His experience also includes similar roles at early-stage life science companies and others in the clean tech sector, as well as consulting roles involving managing financial operations and preparing financial reporting for clients. In 2022, Mr. Rychlik was also a member of a team that supported a successful IPO for Greenlight Biosciences. Prior to that, Mr. Rychlik was a member of a team that supported successful IPOs for Internet Brands Inc. and Ceres Inc., and a venture capital raise for Gevo Inc. Mr. Rychlik has over 15 years’ experience as a controller in traditional manufacturing, where he implemented ERP systems several times as well as efficiency measures improving cash flow and cost savings. He earned a B. Arts at University of Toronto and a B. Commerce at University of Windsor followed by several years in public accounting practice at a regional public accounting firm.

There is no arrangement or understanding between Mr. Rychlik and any other persons pursuant to which Mr. Rychlik was selected as an officer. There are no family relationships between Mr. Rychlik and any of the Company’s directors or executive officers. There are no related person transactions in which Mr. Rychlik has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.

Item 5.07.

Submission of Matters to a Vote of Security Holders.

At the Annual Meeting of Shareholders held on September 14, 2023 (the “Meeting”), the shareholders of the Company elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2024, as follows:

Members	Number of Shares Voted For	Number of Shares Withheld	Broker Non- Votes
Deborah L. Birx, M.D.	29,376,679	307,680	1,204,286
Jules Haimovitz	28,721,661	962,698	1,204,286
Odysseas D. Kostas, M.D.	28,740,184	944,175	1,204,286
Robin C. Kramer	29,478,509	205,850	1,204,286
Joseph M. Patti, Ph. D.	29,478,115	206,244	1,204,286
Todd C. Peterson, Ph. D.	29,483,125	201,234	1,204,286
Sarah Schlesinger, M.D.	28,743,451	940,908	1,204,286

At the Meeting, our shareholders next approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The vote for such approval was 29,620,537 shares for, 49,049 shares against, 14,773 shares abstaining, and 1,204,286 shares of broker non-votes.

Also at the Meeting, our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote for such ratification was 30,850,478 shares for, 37,396 shares against, 771 shares abstaining, and 0 shares of broker non-votes.

- 2 -

Also at the Meeting, our shareholders approved, in accordance with the NYSE American exchange rules, the issuance of our common stock upon conversion, if applicable, of the loan outstanding under our secured convertible credit and security agreement entered into with Innoviva Strategic Opportunities LLC. The vote for such approval was 29,637,787 shares for, 33,901 shares against, 12,671 shares abstaining, and 1,204,286 shares of broker non-votes.

Forward Looking Statements

This Current Report on Form 8-K contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to Armata's plan to transition more of its financing and accounting functions to Armata personnel. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Armata's current expectations. Forward-looking statements involve risks and uncertainties. Armata's actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Armata's plan to transition more of its financing and accounting functions to Armata personnel. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the SEC, including in Armata's Annual Report on Form 10-K, filed with the SEC on March 16, 2023, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

- 3 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 20, 2023	Armata Pharmaceuticals, Inc.

	By:	/s/ Deborah L. Birx
	Name:	Deborah L. Birx
	Title:	Chief Executive Officer

- 4 -

EX-101.SCH 2 armp-20230914.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 armp-20230914_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 armp-20230914_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Sep. 14, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 14, 2023
Entity File Number	001-37544
Entity Registrant Name	ARMATA PHARMACEUTICALS, INC.
Entity Central Index Key	0000921114
Entity Tax Identification Number	91-1549568
Entity Incorporation, State or Country Code	WA
Entity Address, Address Line One	5005 McConnell Avenue
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90066
City Area Code	310
Local Phone Number	655-2928
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	ARMP
Security Exchange Name	NYSEAMER
Entity Emerging Growth Company	false

XML 6 tm2326466d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000921114 2023-09-14 2023-09-14 iso4217:USD shares iso4217:USD shares 0000921114 false 8-K 2023-09-14 ARMATA PHARMACEUTICALS, INC. WA 001-37544 91-1549568 5005 McConnell Avenue Los Angeles CA 90066 310 655-2928 false false false false false Common Stock ARMP NYSEAMER EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://armatapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports armp-20230914.xsd armp-20230914_lab.xml armp-20230914_pre.xml tm2326466d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2326466d1_8k.htm": { "nsprefix": "armp", "nsuri": "http://armatapharma.com/20230914", "dts": { "schema": { "local": [ "armp-20230914.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "armp-20230914_lab.xml" ] }, "presentationLink": { "local": [ "armp-20230914_pre.xml" ] }, "inline": { "local": [ "tm2326466d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://armatapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-09-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2326466d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2326466d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://armatapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001104659-23-102132-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-102132-xbrl.zip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